BRPI0405520A - novas drogas derivadas do diclofenaco contendo heterociclos doadores de no, composição e método de tratamento de inflamação - Google Patents

novas drogas derivadas do diclofenaco contendo heterociclos doadores de no, composição e método de tratamento de inflamação

Info

Publication number
BRPI0405520A
BRPI0405520A BRPI0405520-9A BRPI0405520A BRPI0405520A BR PI0405520 A BRPI0405520 A BR PI0405520A BR PI0405520 A BRPI0405520 A BR PI0405520A BR PI0405520 A BRPI0405520 A BR PI0405520A
Authority
BR
Brazil
Prior art keywords
heterocycles
new
treatment method
drugs containing
drugs
Prior art date
Application number
BRPI0405520-9A
Other languages
English (en)
Inventor
Jose Junior Pedrazzoli
Paulo Sergio De Carvalho
Alessandra Gambero
Original Assignee
Cmax Otimizacao De Resultados
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cmax Otimizacao De Resultados filed Critical Cmax Otimizacao De Resultados
Priority to BRPI0405520-9A priority Critical patent/BRPI0405520A/pt
Priority to US11/665,734 priority patent/US20080114038A1/en
Priority to PCT/BR2005/000202 priority patent/WO2006042387A1/en
Publication of BRPI0405520A publication Critical patent/BRPI0405520A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"NOVAS DROGAS DERIVADAS DO DICLOFENACO CONTENDO HETEROCICLOS DOADORES DE NO, COMPOSIçãO E MéTODO DE TRATAMENTO DE INFLAMAçãO". A presente invenção se refere à novas drogas derivadas do fármaco diclofenaco, compreendendo a fórmula: A invenção se refere ainda a uma composição farmacêutica compreendendo as novas drogas e um veículo farmaceuticamente adequado. Também é descrito um método de tratamento de inflamação através da administração das novas drogas em pacientes com problemas gástricos ou submetidos a tratamentos em longo período.
BRPI0405520-9A 2004-10-21 2004-10-21 novas drogas derivadas do diclofenaco contendo heterociclos doadores de no, composição e método de tratamento de inflamação BRPI0405520A (pt)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BRPI0405520-9A BRPI0405520A (pt) 2004-10-21 2004-10-21 novas drogas derivadas do diclofenaco contendo heterociclos doadores de no, composição e método de tratamento de inflamação
US11/665,734 US20080114038A1 (en) 2004-10-21 2005-09-23 Drugs Derived from Diclofenac Containing No-Donor Heterocycles, Composition and Method of Inflammation Treatment
PCT/BR2005/000202 WO2006042387A1 (en) 2004-10-21 2005-09-23 Drugs derived from diclofenac containing no-donor heterocycles, composition and method of inflammation treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0405520-9A BRPI0405520A (pt) 2004-10-21 2004-10-21 novas drogas derivadas do diclofenaco contendo heterociclos doadores de no, composição e método de tratamento de inflamação

Publications (1)

Publication Number Publication Date
BRPI0405520A true BRPI0405520A (pt) 2006-06-13

Family

ID=36576158

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0405520-9A BRPI0405520A (pt) 2004-10-21 2004-10-21 novas drogas derivadas do diclofenaco contendo heterociclos doadores de no, composição e método de tratamento de inflamação

Country Status (3)

Country Link
US (1) US20080114038A1 (pt)
BR (1) BRPI0405520A (pt)
WO (1) WO2006042387A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US8822509B2 (en) 2006-12-29 2014-09-02 The University Of Queensland Pain-relieving compositions and uses therefor
WO2009037705A2 (en) * 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. Esters of n-phenylanthranilic acid for use in the treatment of cancer and inflammation
EP2203411B1 (en) 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
WO2010000019A1 (en) * 2008-07-02 2010-01-07 The University Of Queensland Pain-relieving compositions of furoxan no donors and uses thereof
WO2020223355A1 (en) * 2019-04-30 2020-11-05 University Of Georgia Research Foundation, Inc. Nickel chelation therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020819A1 (en) * 1995-12-06 1997-06-12 Eli Lilly And Company Composition for treating pain
CN1133626C (zh) * 2001-01-08 2004-01-07 南京长澳医药科技有限公司 双氯芬酸偶联衍生物、其合成方法及抗炎作用

Also Published As

Publication number Publication date
WO2006042387A1 (en) 2006-04-27
US20080114038A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
TWI392670B (zh) 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
BR0315630A (pt) Administração de combinação de uma indolinona com um agente quimioterapêutico para distúrbios de proliferação celular
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
BR0315580A (pt) Derivados de metileno uréia
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
BRPI0507198A (pt) derivados de bisariluréia
EA200801165A1 (ru) Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EA201592040A1 (ru) Иммуногенная композиция для применения в терапии
IL194500A (en) A peptide substance capable of increasing capillary resistance and pharmacological preparation containing the above
EP4389218A3 (en) Composition for treating joint disease and kit containing same
EA201990419A1 (ru) Слаборастворимый комплекс или его сольват, фармацевтическая композиция и их применение
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
BR0315659A (pt) Composição farmacêutica oral para administração uma vez ao dia para a liberação controlada de tramadol ou um sal do mesmo
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
JP7105465B2 (ja) キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物及び懸濁液注射剤の製造方法

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]